Successful Elocta bid means increased access for people with haemophilia A in the UK
Through an agreement with National Health Service (NHS) and Sobi [TM], people living with haemophilia A in the United Kingdom will have increased access to Elocta (efmoroctocog alfa) following a successful bid in the United Kingdom’s haemophilia A tender. Efmoroctocog alfa is licensed by the European Commission in all age groups for treatment and prophylaxis (prevention) of bleeding in patients with haemophilia A (1). It is an extended half-life (EHL) therapy reimbursed by NHS England and as well, suitable for all age ranges and all severities. “Today’s